Altered pathways and targeted therapy in double hit lymphoma.
Yuxin Zhuang1,2, Jinxin Che2,3, Meijuan Wu4
1Department of Lymphoma, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, People's Republic of China.
Journal of Hematology & Oncology
|March 19, 2022
Summary
Double hit lymphoma (DHL), an aggressive blood cancer, has poor outcomes with current treatments. Understanding its genetic alterations offers new therapeutic strategies for better clinical benefits.
Area of Science:
- Hematologic Malignancies
- Cancer Genetics
- Immunology
Background:
- High-grade B-cell lymphoma with MYC and BCL2 or BCL6 translocations, known as double hit lymphoma (DHL), is aggressive with poor prognosis.
- Standard chemoimmunotherapy and targeted therapies for DHL remain limited, necessitating novel treatment approaches.
Purpose of the Study:
- To summarize genetic alterations in DHL subtypes (DHL-BCL2 and DHL-BCL6).
- To elucidate the implications of these alterations on cellular processes like apoptosis, epigenetics, B-cell receptor signaling, and immune escape.
- To review current and potential therapeutic strategies targeting these genetic changes.
Main Methods:
- Literature review and synthesis of genetic alterations in DHL.
- Analysis of the impact of genetic changes on key cellular pathways.
- Review of ongoing and proposed targeted therapies for DHL.
Main Results:
- Identified distinct genetic alterations in DHL-BCL2 and DHL-BCL6 subtypes.
- Elucidated how these alterations affect anti-apoptosis, epigenetic regulation, B-cell receptor signaling, and immune evasion.
- Highlighted therapeutic vulnerabilities linked to specific genetic changes.
Conclusions:
- Understanding DHL's genetic landscape is crucial for developing more effective treatments.
- Targeting specific genetic alterations and vulnerabilities may improve clinical outcomes for DHL patients.
- Further research into DHL's molecular pathways can unlock new therapeutic avenues.
Related Concept Videos
02:57Targeted Cancer Therapies
7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.9K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
01:31The Intrinsic Apoptotic Pathway
6.9K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.9K
01:27Tumor Immunotherapy
699
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
699
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:19Interactions Between Signaling Pathways
6.6K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K